Clinical trials for lung cancer
129 currently recruiting clinical trials
If you are a doctor and would like find matching clinical trials for you patients, create an account or log in
If you are a patient and would like to know if you may participate in a clinical trial, please consult your doctor so that he can send your file to a matching trial
Phase 1 / Phase 2
Lung cancer
#NCT04585750
Locally Advanced
Metastatic
TP53
1
2
3 or more
KRAS G12C
KRAS non G12C
Systemic Treatment-Naive
IUCT Oncopôle (Toulouse), Centre Léon Bérard (Lyon), Centre Hospitalier Universitaire de Nîmes (Nîmes), ICANS - Institut de cancérologie Strasbourg Europe (Strasbourg), Gustave Roussy (Villejuif) (and 3 more...)
PMV Pharmaceuticals, Inc
Phase 1 / Phase 2
Lung cancer
#NCT06162572
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
PDL1 Positive (>= 50%)
Systemic Treatment-Naive
ALK
EGFR
ROS-1
Immunotherapy
Immunotherapy
CGFL Dijon - Centre Régional De Lutte Contre Le Cancer Georges - François Leclerc (Dijon ), Institut Paoli-Calmettes (Marseille), Gustave Roussy (Villejuif), Centre Hospitalier Universitaire de Grenoble (La Tronche), Institut de Cancérologie de l'Ouest - Site de Saint-Herblain (Saint-Herblain)
Servier
Phase 1 / Phase 2
Lung cancer
#NCT05937906
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Locally Advanced
Metastatic
PDL1 Negative (< 1%)
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
None
Systemic Treatment-Naive
ALK
EGFR
ROS-1
CGFL Dijon - Centre Régional De Lutte Contre Le Cancer Georges - François Leclerc (Dijon )
Centre Georges François Leclerc
Phase 1 / Phase 2
Lung cancer
#NCT06448572
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
1
2
3 or more
Immunotherapy
Chemotherapy
ALK
BRAF
EGFR
HER2
MET
RET
ROS-1
Centre Hospitalier Universitaire de Lille (Lille)
CHU Lille
Phase 1 / Phase 2
Lung cancer
#NCT05592626
NSCLC (Non-Small Cell Lung Cancer)
Metastatic
MSI/dMMR
1
2
3 or more
Gustave Roussy (Villejuif), Institut Bergonié (Bordeaux)
Marengo Therapeutics, Inc.
Phase 1 / Phase 2
Lung cancer
#NCT04626635
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
EGFR
Chemotherapy
Targeted therapy
Systemic Treatment-Naive
Immunotherapy
CGFL Dijon - Centre Régional De Lutte Contre Le Cancer Georges - François Leclerc (Dijon ), Hôpital Lyon Sud - Hospices Civils de Lyon (Pierre-Bénite), Hôpital d'instruction des Armées Bégin (Saint-Mandé), Institut Bergonié (Bordeaux), Centre Léon Bérard (Lyon) (and 5 more...)
Regeneron Pharmaceuticals
Phase 1 / Phase 2
Lung cancer
#NCT04626635
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
Systemic Treatment-Naive
Immunotherapy
CGFL Dijon - Centre Régional De Lutte Contre Le Cancer Georges - François Leclerc (Dijon ), Hôpital Lyon Sud - Hospices Civils de Lyon (Pierre-Bénite), Hôpital d'instruction des Armées Bégin (Saint-Mandé), Institut Bergonié (Bordeaux), Centre Léon Bérard (Lyon) (and 5 more...)
Regeneron Pharmaceuticals
Phase 1 / Phase 2
Lung cancer
#NCT04143711
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
HER2
1
2
3 or more
Immunotherapy
Chemotherapy
Systemic Treatment-Naive
Institut du cancer de Montpellier (Montpellier), CGFL Dijon - Centre Régional De Lutte Contre Le Cancer Georges - François Leclerc (Dijon ), Hôpital Pitié Salpêtrière - AP-HP (Paris), Groupe Hospitalier Saint André (Bordeaux), Centre Oscar Lambret (Lille) (and 5 more...)
Dragonfly Therapeutics
Phase 1 / Phase 2
#NCT05544552
Locally Advanced
Metastatic
FGFR
Systemic Treatment-Naive
Institut de Cancérologie de l'Ouest - Site de Saint-Herblain (Saint-Herblain), IUCT Oncopôle (Toulouse), Gustave Roussy (Villejuif)
Tyra Biosciences, Inc